

## MASTER'S THESIS

### Anti-cancer effect of ginsenosides on nasopharyngeal carcinoma

Law, Ka Man Carmen

*Date of Award:*  
2012

[Link to publication](#)

#### General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

# **Anti-cancer Effect of Ginsenosides on Nasopharyngeal Carcinoma**

LAW Ka Man, Carmen

A thesis submitted in partial fulfillment of the requirements  
for the degree of  
Master of Philosophy

Principal Supervisor: Prof. WONG Ricky Ngok Shun

Hong Kong Baptist University

August 2012

## Abstract

Nasopharyngeal carcinoma (NPC) is a head and neck cancer which has a high incidence rate in Southern China. Radiotherapy, chemotherapy and radiochemotherapy are the current therapies commonly used on NPC patients. However, these therapies have the problems of side effects, chemoresistance and toxicity. In view of this, alternative therapy is needed.

In the first part of my study, the anti-cancer effect of ginsenosides on NPC cells was investigated. Ginsenosides are the active compound in ginseng. NPC cell lines: HK-1 and C666-1 cells were used at the beginning of this study. Later on, only HK-1 cells were studied because of its sensitivity towards ginsenosides. It was shown that five ginsenosides: protopanaxadiol (PPD), panaxadiol (PD), compound K (CK), 20(S)-Rh<sub>2</sub> and Rp1 exhibited higher cytotoxicity and induced apoptosis on NPC cells. The mitogen-activated protein kinase (MAPK) signaling pathways were revealed to be independent of the ginsenoside-induced cell death. Besides, it was found that ginsenosides modulated the ROS level in NPC cells, but relationship was not conclusive. Furthermore, ginsenoside-induced caspase-3, -8 and -9 activations were shown to be independent of the cell death. Apart from that, ginsenoside CK was found to induce depolarization of mitochondrial membrane potential as well as translocation of apoptosis-inducing factor (AIF) from cytoplasm to nucleus. This study suggested that the ginsenoside-induced cell death was mediated through the mitochondrial apoptotic pathway.

The second part was about the effect of NPC cell conditioned medium on human umbilical vein endothelial cells (HUVECs). In tumor microenvironment, tumor cells secrete various angiogenic and migratory factors affecting the behavior of HUVECs. In this study, it was found that both NPC cell conditioned media induced angiogenesis and migration of HUVECs. Furthermore, the vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) expressions in both NPC cell conditioned media were higher than uncultured medium. This indicated that the NPC cells may affect the HUVECs behavior through secretion of VEGF and MMPs.

The third part was to study the anti-cancer effect of Cetuximab with conventional anti-cancer drugs, cisplatin or docetaxel, on both NPC cells. The use of anti-epidermal growth factor receptor (EGFR) antagonist with current chemotherapy on NPC patients has been reported in clinical studies. However, *in vitro* study about this issue is lacking. In the present study, the cotreatment with Cetuximab did not show significant synergistic effect on the anti-cancer effect of cisplatin or docetaxel in both NPC cell lines by MTT assay. This study shed light

on the clinical trial that this combination of drugs and treatment schedule may not have beneficial effect on NPC therapy.

Taken together, the anti-cancer effect and underlying mechanism of ginsenosides on NPC cells has been demonstrated in this study. The angiogenic effect of NPC cells on HUVECs was also studied, in which further investigation with anti-angiogenic therapy on NPC cells was suggested. In addition, the anti-cancer effect of Cetuximab with cisplatin or docetaxel was revealed. Alternative combination of drugs and treatment schedule were recommended.

# Table of Contents

Declaration .....	i
Abstract .....	ii
Acknowledgements .....	iv
Table of Contents .....	v
List of Tables .....	viii
List of Figures .....	ix
List of Abbreviations .....	xii
<b>Chapter 1 Introduction.....</b>	<b>1</b>
1.1. <i>Panax ginseng</i> C.A. Meyer and ginsenosides .....	1
1.1.1. <i>Panax ginseng</i> C.A. Meyer.....	1
1.1.2. Ginsenosides .....	1
1.1.2.1. Structure of ginsenosides .....	2
1.1.2.2. Pharmacological effects of ginsenosides.....	5
1.1.2.3. Anti-cancer effects of ginsenosides.....	8
1.1.2.4. Commercial products of ginsenosides .....	10
1.2. Nasopharyngeal carcinoma (NPC).....	11
1.2.1. Classification of NPC .....	12
1.2.2. Epidemiology of NPC.....	12
1.2.3. Causes of NPC .....	17
1.2.3.1. Environmental factors .....	17
1.2.3.2. Epstein-Barr Virus (EBV) .....	19
1.2.3.3. Molecular alterations.....	20
1.2.4. Molecular mechanisms related to NPC .....	22
1.2.4.1. MAPK signaling pathway .....	22
1.2.4.2. Epidermal growth factor receptor (EGFR) signaling pathway ..	24
1.2.4.3. Oxidative stress .....	27
1.2.5. Current NPC treatments.....	29
1.2.5.1. Radiotherapy .....	29
1.2.5.2. Chemotherapy .....	30
1.2.5.2.1. Conventional cytotoxic drugs .....	30
1.2.5.2.2. Targeted therapy .....	32
1.2.5.3. Anti-angiogenic therapy .....	34
1.3. Cell death mechanism – Apoptosis .....	35
1.3.1. Role of apoptosis .....	35
1.3.2. Molecular regulation of apoptosis .....	36
1.3.2.1. Caspase cascade .....	37
1.3.2.2. Apoptosis-inducing factor (AIF).....	39

1.3.3. Induction of apoptosis in cancer therapy .....	40
1.4. Objectives.....	42
<b>Chapter 3 Materials and Methods.....</b>	<b>43</b>
3.1. Materials.....	43
3.2. Cell lines and treatments .....	45
3.3. Cell viability assay .....	45
3.4. Cell cycle analysis.....	47
3.5. Western blotting analysis.....	47
3.6. Cellular subfractionation.....	48
3.7. Reactive Oxygen Species (ROS) detection.....	49
3.8. Mitochondrial membrane potential .....	50
3.9. Immunofluorescence assay .....	50
3.10. Tube formation assay .....	51
3.11. Wound healing assay .....	52
3.12. Gelatin zymography .....	53
3.13. Statistical analysis .....	54
<b>Chapter 4 Results.....</b>	<b>55</b>
4.1. Mechanistic study on the anti-cancer effect of ginsenosides on NPC cells	55
4.1.1. Ginsenosides PPD, PD, CK, 20(S)-Rh <sub>2</sub> and Rp1 exhibited high cytotoxicities towards NPC cells.....	55
4.1.2. Ginsenosides-induced apoptosis in NPC cells .....	61
4.1.3. Ginsenosides-induced cell death was independent of MAPK signaling pathways .....	67
4.1.4. Ginsenoside-induced cell death was related to ROS level .....	70
4.1.5. CK-induced caspase-independent apoptosis in HK-1 cells.....	77
4.1.6. CK-induced apoptosis-inducing factor (AIF) translocation and mitochondrial membrane depolarization in HK-1 cells.....	84
4.2. Effect of NPC cell conditioned medium on human umbilical vein endothelial cells (HUVECs) .....	87
4.2.1. Conditioned medium of NPC cells induced angiogenesis on HUVECs .....	88
4.2.2. Vascular endothelial growth factor (VEGF) expression in conditioned medium of NPC cells was higher than uncultured medium .....	91
4.2.3. Conditioned medium of NPC cells induced migration of HUVECs ..	92
4.2.4. Expression of matrix metalloproteinases (MMPs) in conditioned medium of NPC cells was higher than uncultured medium .....	95
4.3. Study on the anti-cancer effect of Cetuximab with cisplatin or docetaxel..	96
4.3.1. Cytotoxicities of Cetuximab on NPC cells.....	97

4.3.2. Co-treatment of Cetuximab with cisplatin or docetaxel did not have synergistic effects on NPC cells .....	99
<b>Chapter 5 Discussions.....</b>	<b>102</b>
5.1. Mechanistic study on the anti-cancer effect of ginsenosides on NPC cells .....	102
5.2. Effect of NPC cell conditioned medium on human umbilical vein endothelial cells (HUVECs) .....	113
5.3. Study on the anti-cancer effect of Cetuximab with cisplatin or docetaxel	117
<b>Chapter 6 Conclusions.....</b>	<b>121</b>
6.1. Mechanistic study on the anti-cancer effect of ginsenosides on NPC cells .....	121
6.2. Effect of NPC cell conditioned medium on human umbilical vein endothelial cells (HUVECs) .....	123
6.3. Study on the anti-cancer effect of Cetuximab with cisplatin or docetaxel	125
<b>Chapter 7 Further investigations .....</b>	<b>126</b>
<b>List of References.....</b>	<b>128</b>
<b>List of Publication.....</b>	<b>147</b>
<b>Curriculum Vitae .....</b>	<b>148</b>